Jefferies has increased its price target for Summit Therapeutics (SMMT, Financial) from $31 to $44, maintaining a Buy rating for the stock. This adjustment follows the approval of Ivonescimab in China for use in first-line platinum-based chemotherapy for patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The Chinese National Medical Products Administration has officially posted this approval.
The analyst expressed optimism regarding Summit's prospects, particularly in light of the HARMONi-2 study results. Furthermore, the recent HARMONi-6 topline data and the success in China have led Jefferies to increase the projected success rate for Summit's ongoing global trials, namely HARMONi-7 and HARMONi-3, which focus on first-line NSCLC treatments.
The approval in China represents Ivonescimab’s second milestone in NSCLC, targeting a considerably larger patient population compared to its initial approval. The firm's continued confidence underscores a potential upward trajectory for Summit's shares.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Summit Therapeutics Inc (SMMT, Financial) is $31.00 with a high estimate of $44.00 and a low estimate of $5.00. The average target implies an downside of 8.35% from the current price of $33.83. More detailed estimate data can be found on the Summit Therapeutics Inc (SMMT) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Summit Therapeutics Inc's (SMMT, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Summit Therapeutics Inc (SMMT, Financial) in one year is $0.39, suggesting a downside of 98.85% from the current price of $33.825. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Summit Therapeutics Inc (SMMT) Summary page.
SMMT Key Business Developments
Release Date: February 24, 2025
- Cash Position: Approximately $412 million at the end of 2024.
- Debt Status: Debt-free as of the end of 2024.
- GAAP R&D Expenses: $150.8 million for the full year 2024, up from $59.4 million in the previous year.
- Non-GAAP R&D Expenses: $134.8 million for the full year 2024, compared to $55 million in the previous year.
- Acquired In-Process R&D Expenses: $15 million for 2024, down from $520.9 million in the previous year.
- GAAP G&A Expenses: $60.5 million for the full year 2024, compared to $30.3 million in the previous year.
- Non-GAAP G&A Expenses: $25.5 million for the full year 2024, compared to $20.6 million in the prior year.
- Non-GAAP Operating Expenses: $175.3 million for the full year 2024, down from $596.5 million in the previous year.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Summit Therapeutics Inc (SMMT, Financial) announced a clinical trial collaboration with Pfizer to evaluate Ivonescimab in combination with multiple Pfizer antibody drug conjugates in unique solid tumor settings.
- The company completed enrollment and received Fast Track designation for its global Phase III trial, HARMONi, targeting EGFR mutated advanced non-small cell lung cancer.
- Summit Therapeutics Inc (SMMT) expanded the HARMONi-3 trial to include a larger patient population, addressing both squamous and non-squamous histologies.
- The company has a strong cash position of approximately $412 million and is debt-free, providing a solid financial foundation for ongoing and future trials.
- Ivonescimab has been featured in numerous publications and presentations, indicating strong interest and recognition in the medical community.
Negative Points
- The company's R&D expenses increased significantly to $150.8 million in 2024 from $59.4 million in the previous year, reflecting the expansion of clinical trials.
- There is uncertainty regarding the timing of the HARMONi-2 overall survival data, which is crucial for regulatory approval processes.
- Summit Therapeutics Inc (SMMT) faces challenges in providing a clear timeline for the top-line readout of the HARMONi-3 trial due to ongoing site activations.
- The company has not disclosed specific details about the Pfizer collaboration, such as which ADCs will be used or the tumor types targeted, leaving some strategic aspects unclear.
- The competitive landscape in non-small cell lung cancer is intense, with multiple ongoing Phase III studies by other companies, which could impact market share and approval timelines.
